<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:mp ids='MP_0005601'>Enhanced angiogenesis</z:mp> facilitates neurovascular remodeling processes and promotes brain functional recovery after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies from our laboratory demonstrated that valproate (VPA), a <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor, protects against experimental <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The present study investigated whether VPA could enhance <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and promote long-term functional recovery after <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Male rats underwent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 60 minutes followed by reperfusion for up to 14 days </plain></SENT>
<SENT sid="4" pm="."><plain>Assessed parameters were: locomotor function through the Rotarod test; <z:mpath ids='MPATH_124'>infarct</z:mpath> volume through T2-weighted MRI; microvessel density through immunohistochemistry; relative cerebral blood flow through perfusion-weighted imaging; protein levels of proangiogenic factors through Western blotting; and matrix metalloproteinase-2/9 activities through gelatin zymography </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Postischemic VPA treatment robustly improved the Rotarod performance of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> rats on Days 7 and 14 after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and significantly reduced <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> on Day 14 </plain></SENT>
<SENT sid="6" pm="."><plain>Concurrently, VPA markedly enhanced microvessel density, facilitated endothelial cell proliferation, and increased relative cerebral blood flow in the ipsilateral cortex </plain></SENT>
<SENT sid="7" pm="."><plain>The transcription factor <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α and its downstream proangiogenic factors, vascular endothelial growth factor and matrix metalloproteinase-2/9, were upregulated after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and significantly potentiated by VPA in the ipsilateral cortex </plain></SENT>
<SENT sid="8" pm="."><plain>Acetylation of <z:chebi fb="0" ids="15358">histone</z:chebi>-H3 and H4 was robustly increased by <z:hpo ids='HP_0011010'>chronic</z:hpo> VPA treatment </plain></SENT>
<SENT sid="9" pm="."><plain>The beneficial effects of VPA on Rotarod performance and microvessel density were abolished by <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α inhibition </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0011010'>Chronic</z:hpo> VPA treatment enhances <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and promotes functional recovery after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>These effects may involve <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibition and upregulation of <z:mp ids='MP_0005039'>hypoxia</z:mp>-inducible factor-1α and its downstream proangiogenic factors vascular endothelial growth factor and matrix metalloproteinase-2/9 </plain></SENT>
</text></document>